论文部分内容阅读
麦迪霉素为大环内酯类新抗生素,对革兰氏阳性球菌和部分革兰氏阴性杆菌有较强的抑菌作用,且不易产生诱导耐药。口服制剂治疗呼吸道、皮肤软组织等急性化脓性感染疗效显著,副作用小。但血药浓度不够高,不利于治疗重症感染。为了提高血药浓度,扩大临床应用范围,四川抗菌素工业研究所研制了麦迪霉素静脉注射液制剂。目前尚未见国外有注射剂制剂的报告。我们于近期首批试用以治疗急性化脓性感染120例,现将临床观察结果报道如下。
Midecamycin is a new macrolide antibiotic, Gram-positive cocci and some Gram-negative bacilli have strong antibacterial activity, and not easy to induce drug resistance. Oral preparations for the treatment of respiratory tract, skin and soft tissue acute suppurative infection has a significant effect, small side effects. However, blood concentration is not high enough, is not conducive to the treatment of severe infections. In order to increase blood concentration and expand the scope of clinical application, Sichuan Institute of Antibiotics developed a midecamycin intravenous solution. There are no reports of injectable preparations abroad. We first trial in the near future to treat 120 cases of acute suppurative infection, the clinical observations are reported below.